Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 1.1% – Time to Sell?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)’s share price fell 1.1% during mid-day trading on Tuesday . The stock traded as low as $3.42 and last traded at $3.45. 12,917 shares changed hands during trading, a decline of 83% from the average session volume of 75,676 shares. The stock had previously closed at $3.49.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Kiora Pharmaceuticals in a research report on Thursday, August 22nd.

Kiora Pharmaceuticals Trading Down 1.1 %

The company has a fifty day moving average of $3.55 and a two-hundred day moving average of $4.41.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.42. The firm had revenue of $0.02 million for the quarter. Research analysts forecast that Kiora Pharmaceuticals, Inc. will post 1.17 earnings per share for the current year.

Institutional Trading of Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC purchased a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals comprises 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th biggest holding. Stonepine Capital Management LLC owned about 6.86% of Kiora Pharmaceuticals as of its most recent SEC filing. 76.97% of the stock is owned by institutional investors and hedge funds.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.